Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10372506 | 0.77 | CHRM2 (0.44) | CHRM4JAK3SLC6A9ACACB | |
| SCHEMBL27233831 | 0.76 | CHRM2 (0.46) | CHRM4SLC6A9 | |
| SCHEMBL10371900 | 0.76 | CHRM2 (0.46) | CHRM4SLC6A9 | |
| SCHEMBL27233824 | 0.76 | CHRM2 (0.46) | CHRM4SLC6A9 | |
| SCHEMBL10849119 | 0.75 | GRM1 (0.47) | CHRM4TSHRALDH1A1GAAHPGD | |
| SCHEMBL10372937 | 0.74 | SLC6A7 (0.42) | CHRM4TSHRALDH1A1 | |
| SCHEMBL10374711 | 0.72 | L3MBTL1 (0.42) | SLC6A9 | |
| SCHEMBL25192004 | 0.71 | TRPC6 (0.38) | CHRM4JAK3SLC6A9MAPK1 | |
| SCHEMBL10373604 | 0.71 | SLC6A7 (0.50) | GPBAR1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10373568 | 0.70 | ACACB (0.46) | ALDH1A1ACACBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4994460-A | Treatment or prevention of disorders resulting from central nervous system anoxia | BRISTOL-MYERS SQUIBB CO. (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0400661-A1 | Agents for treatment of brain ischemia | Bristol-Myers Squibb Company (US) | 1990-12-05 | — | — | EP | disclosed |